Denali Therapeutics Inc
F:4DN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Denali Therapeutics Inc
F:4DN
|
US |
|
P
|
Panasonic Holdings Corp
XMUN:MAT1
|
JP |
|
Gofore Oyj
LSE:0CXS
|
FI |
|
PLC SpA
MIL:PLC
|
IT |
|
Keystone Law Group PLC
LSE:KEYS
|
UK |
|
Dal'nevostochnoye Morskoye Parokhodstvo PAO
MOEX:FESH
|
RU |
|
Apollo Global Management Inc
F:N7I
|
US |
|
Delota Corp
F:S62
|
CA |
Earnings Calls
Last Earnings Call
Launch momentum: Denali said Avalaya had a strong first full commercial quarter, with $3.6 million in net product revenue and commercial coverage for more than 50% of lives.
Q3 outlook: Management guided Q3 net product revenue to $10 million to $12 million, saying early demand has been stronger than expected and launch indicators are trending positively.
Pipeline progress: Two Alzheimer’s programs, DNL628 and DNL921, advanced into clinical development, with initial data expected in 2027.
Cash strength: The company ended the quarter with about $940 million in cash, and July proceeds from a priority review voucher lifted pro forma cash above $1.1 billion.
Launch questions: In Q&A, management said the early launch appears to include a larger-than-expected “bolus” of highly engaged families, but they expect momentum to broaden beyond the initial group.